Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Open

14.66 4.05

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.04

Max

14.68

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+109.37% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	130M 1.3B
Vorige openingsprijs	10.61
Vorige sluitingsprijs	14.66

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 aug 2026, 23:56 UTC

Community Healthcare Trust Inc. shares are lower in after-market hours amid broader market caution related to geopolitical tensions and new U.S.-Iran sanctions.

24 aug 2026, 23:56 UTC

Ares Capital Corp shares are trading roughly flat in after-hours. The stock remains above its 20-day moving average amid broader market caution.

24 aug 2026, 23:56 UTC

Social Media

DICK'S Sporting Goods shares are higher in after-market trading as investors await earnings announcement tomorrow, despite earlier pulling back from a session high.

24 aug 2026, 23:56 UTC

Dillard's Inc shares are lower in after-market hours amid cautious market sentiment influenced by geopolitical tensions and economic concerns.

24 aug 2026, 23:56 UTC

Axon Enterprise Inc. shares advanced in after-market trading, following a higher close on Monday amid heightened market caution regarding U.S.-Iran relations and new sanctions.

24 aug 2026, 23:56 UTC

Dycom Industries Inc shares are higher in after-market trading, reflecting a positive shift after five consecutive sessions of lower closes.

24 aug 2026, 23:56 UTC

Vontier Corp shares traded roughly flat in after-market hours, remaining within a routine range since Monday's close.

24 aug 2026, 23:56 UTC

Resmed Inc. shares are lower in after-market hours amid weak trading sentiment. No specific company news was identified to explain the decline.

24 aug 2026, 23:56 UTC

Morgan Stanley shares are higher in after-market trading following Monday's close. The stock reached a session high earlier in the session.

24 aug 2026, 23:56 UTC

Kanzhun Ltd shares increased in after-market trading, despite no specific news. Investor caution remains amid concerns over U.S.-Iran relations and economic implications.

24 aug 2026, 23:56 UTC

Gogo Inc. shares are lower in after-market trading, continuing a decline since Monday amid broader market caution over geopolitical tensions and oil supply concerns.

24 aug 2026, 23:56 UTC

Textron Inc shares are lower in after-market hours amid broader market caution linked to U.S.-Iran tensions and new sanctions affecting oil supply.

24 aug 2026, 23:56 UTC

Dominion Energy shares are higher in after-market trading, reflecting a modest increase since Monday's close. The stock remains below its 20-day moving average.

24 aug 2026, 23:56 UTC

Chipotle Mexican Grill Inc shares are lower in after-market hours amid broader market caution linked to geopolitical tensions and new sanctions affecting economic conditions.

24 aug 2026, 23:56 UTC

Mid-America Apartment Communities shares are lower in after-market hours, reflecting notable volatility amid cautious broader market sentiment over geopolitical tensions.

24 aug 2026, 23:56 UTC

Kulicke and Soffa Industries shares are higher in after-market hours, reflecting positive movement since Monday's close amid broader market caution.

24 aug 2026, 23:56 UTC

Watsco Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines and remaining below the 20-day moving average.

24 aug 2026, 23:56 UTC

NRG Energy Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing investor sentiment amid concerns over U.S.-Iran relations.

24 aug 2026, 23:56 UTC

Markel Group Inc. shares declined in after-market trading amid broader market caution related to geopolitical tensions and new sanctions, now 2.90% below its 20-day moving average.

24 aug 2026, 23:56 UTC

Match Group Inc shares are lower in after-market trading. Broader market caution persists amid concerns over U.S.-Iran relations and oil supply disruptions.

24 aug 2026, 23:56 UTC

General Mills Inc shares are lower in after-market hours, reflecting volatility amid broader market caution over U.S.-Iran relations and potential oil supply disruptions.

24 aug 2026, 23:56 UTC

Correlated Moves

The US 30Y Treasury Bond Index is trading lower amid market caution over U.S.-Iran tensions and new sanctions impacting oil supply concerns.

24 aug 2026, 23:52 UTC

APA Corp. shares are trading higher in after-market hours, reflecting a routine move. The stock has seen notable gains over the past month.

24 aug 2026, 23:51 UTC

Hyatt Hotels Corp shares are lower in after-market hours, following a notable dip earlier amid volatility in U.S. Treasury yields and inflation concerns.

24 aug 2026, 23:51 UTC

HP Inc. shares are lower in after-market hours, reversing a recent trend of higher daily closes despite an earlier rebound from session lows.

24 aug 2026, 23:51 UTC

Shares of Science Applications International Corp. are lower in after-market trading, declining from earlier session peaks amid no specific news or developments.

24 aug 2026, 23:51 UTC

ArcBest Corp shares are lower in after-market hours, continuing weak trading conditions. The stock remains below its 20-day moving average and near recent lows.

24 aug 2026, 23:51 UTC

PENN Entertainment Inc shares are higher in after-market trading, despite remaining near the lower end of their one-month range and below the 20-day moving average.

24 aug 2026, 23:51 UTC

Correlated Moves

Social Media

SPDR Gold Shares are higher in after-market hours, continuing a recent upward trend amid mixed global equity indices and rising silver prices.

24 aug 2026, 23:51 UTC

Deluxe Corp's shares are lower in after-market trading, reflecting weaker performance below its 20-day moving average and near the lower end of its one-month range.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

109.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 109.37%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.